Patents by Inventor Stephen R. Targan

Stephen R. Targan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240254449
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Application
    Filed: April 4, 2024
    Publication date: August 1, 2024
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 11952592
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: April 9, 2024
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Publication number: 20220282221
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Application
    Filed: February 23, 2022
    Publication date: September 8, 2022
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 11326149
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 10, 2022
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Publication number: 20190031992
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Application
    Filed: July 31, 2018
    Publication date: January 31, 2019
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 8766034
    Abstract: This invention relates transgenic animals that overexpress TL1A in a tissue specific manner to model inflammatory bowel disease (IBM such as colitis, Crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. TL1A transgenic animals constitutively express both TL1A and GFP in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in IBD disease progression, such as T-cells, antigen presenting cells (APC), and dendritic cells (DC). TL1A transgenic animals may be induced to exhibit gross fibrosis, or isolated cells may be implanted into immunodeficient mice to establish colitis.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: July 1, 2014
    Assignee: Cedars-Sinai Medical Center
    Inventors: David Q. Shih, Stephen R. Targan
  • Patent number: 8163501
    Abstract: The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: April 24, 2012
    Assignee: Cedars-Sinai Medical
    Inventors: Stephen R. Targan, Eric A. Vasiliauskas, William S. Mow, Huiying Yang, Phillip R. Fleshner, Jerome I. Rotter
  • Publication number: 20120079611
    Abstract: This invention relates transgenic animals that overexpress TL1A in a tissue specific manner to model inflammatory bowel disease (IBM such as colitis, Crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. TL1A transgenic animals constitutively express both TL1A and GFP in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in IBD disease progression, such as T-cells, antigen presenting cells (APC), and dendritic cells (DC). TL1A transgenic animals may be induced to exhibit gross fibrosis, or isolated cells may be implanted into immunodeficient mice to establish colitis.
    Type: Application
    Filed: September 22, 2011
    Publication date: March 29, 2012
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: David Q. Shih, Stephen R. Targan